Skip to main content
Fig. 3 | BMC Gastroenterology

Fig. 3

From: Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review

Fig. 3

Time to first outcome by index treatment and prior biologic exposure. Kaplan-Meier time to first outcome in patients with ulcerative colitis (panels a-c) or Crohn’s disease (panels d-f) by index treatment (vedolizumab vs anti-tumor necrosis factor alpha [anti-TNFα]) and prior biologic exposure (biologic-naïve vs one previous anti-TNFα agent)

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us